View Future GrowthBiotoxtech 過去の業績過去 基準チェック /26Biotoxtechの収益は年間平均-50.8%の割合で減少していますが、 Life Sciences業界の収益は年間 減少しています。収益は年間1.8% 8.9%割合で 増加しています。主要情報-50.78%収益成長率-50.92%EPS成長率Life Sciences 業界の成長53.72%収益成長率8.86%株主資本利益率-4.93%ネット・マージン2.47%前回の決算情報31 Dec 2025最近の業績更新分析記事 • Dec 27We're Not So Sure You Should Rely on Biotoxtech's (KOSDAQ:086040) Statutory EarningsAs a general rule, we think profitable companies are less risky than companies that lose money. Having said that...すべての更新を表示Recent updatesお知らせ • Mar 17Biotoxtech Co., Ltd., Annual General Meeting, Mar 27, 2026Biotoxtech Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: sky garden hall, 5806, jungbu-ro, cheongwon-gu, chungcheongbuk-do, cheongju South KoreaNew Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (7.6% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩44.8b market cap, or US$30.6m).Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩3,190, the stock trades at a trailing P/E ratio of 57x. Average trailing P/E is 17x in the Life Sciences industry in South Korea. Total loss to shareholders of 62% over the past three years.New Risk • Nov 16New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 7.6% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (7.6% operating cash flow to total debt). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩42.6b market cap, or US$29.3m).分析記事 • Sep 01Improved Revenues Required Before Biotoxtech Co., Ltd. (KOSDAQ:086040) Shares Find Their FeetYou may think that with a price-to-sales (or "P/S") ratio of 1.1x Biotoxtech Co., Ltd. ( KOSDAQ:086040 ) is definitely...お知らせ • Aug 27Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces an Equity Buyback for KRW 1,000 million worth of its shares.Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million worth of its shares under the contract with Eugene Investment & Securities. The purpose of the program is to stabilize the stock price, to enhance the shareholders’ value. The program will be valid till February 26, 2026. As of August 26, 2025, the company had 237,458 shares in treasury under the dividend capacity and 0 shares in treasury under other capacities.お知らせ • Mar 15Biotoxtech Co., Ltd., Annual General Meeting, Mar 28, 2025Biotoxtech Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 806, jungbu-ro, cheongwon-gu, chungcheongbuk-do, cheongju South KoreaNew Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩53.7b market cap, or US$37.4m).分析記事 • Oct 21Improved Revenues Required Before Biotoxtech Co., Ltd. (KOSDAQ:086040) Shares Find Their FeetBiotoxtech Co., Ltd.'s ( KOSDAQ:086040 ) price-to-sales (or "P/S") ratio of 2.2x might make it look like a buy right...お知らせ • Jul 30Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces an Equity Buyback for KRW 1,000 million worth of its shares.Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million worth of its shares under the contract with Eugene Investment & Securities. The purpose of the program is to stabilize the stock price, to enhance the shareholders’ value. The program will be valid till January 29, 2025. As of July 29, 2024, the company had 30,735 shares in treasury under the dividend capacity and 0 shares in treasury under other capacities.New Risk • Nov 28New major risk - Revenue and earnings growthEarnings have declined by 0.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 0.2% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (8.8% increase in shares outstanding). Market cap is less than US$100m (₩95.1b market cap, or US$73.4m).New Risk • Jun 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (65% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (0.5% net profit margin). Shareholders have been diluted in the past year (8.8% increase in shares outstanding). Market cap is less than US$100m (₩123.1b market cap, or US$95.0m).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Jun 22Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩7,110, the stock trades at a trailing P/E ratio of 15.6x. Average trailing P/E is 27x in the Life Sciences industry in South Korea. Total returns to shareholders of 3.6% over the past three years.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Feb 18Investor sentiment improved over the past weekAfter last week's 31% share price gain to ₩8,990, the stock trades at a trailing P/E ratio of 32.5x. Average trailing P/E is 25x in the Life Sciences industry in South Korea. Negligible returns to shareholders over past three years.お知らせ • Aug 25Biotoxtech Co., Ltd. announced that it has received KRW 18 billion in funding from BNK Securities Co., Ltd., Investment Arm, Mirae Asset Securities Co., Ltd. and other investorsOn August 24, 2021, Biotoxtech Co., Ltd. closed the transaction.お知らせ • Aug 21Biotoxtech Co., Ltd. announced that it expects to receive KRW 18000 billion in funding from BNK Securities Co., Ltd., Investment ArmBiotoxtech Co., Ltd.分析記事 • May 06Is Biotoxtech (KOSDAQ:086040) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Mar 28Estimating The Fair Value Of Biotoxtech Co., Ltd. (KOSDAQ:086040)Today we will run through one way of estimating the intrinsic value of Biotoxtech Co., Ltd. ( KOSDAQ:086040 ) by...分析記事 • Feb 20Did Biotoxtech's (KOSDAQ:086040) Share Price Deserve to Gain 91%?Some Biotoxtech Co., Ltd. ( KOSDAQ:086040 ) shareholders are probably rather concerned to see the share price fall 32...Is New 90 Day High Low • Feb 18New 90-day low: ₩11,200The company is down 29% from its price of ₩15,700 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 2.0% over the same period.分析記事 • Jan 24Are Robust Financials Driving The Recent Rally In Biotoxtech Co., Ltd.'s (KOSDAQ:086040) Stock?Most readers would already be aware that Biotoxtech's (KOSDAQ:086040) stock increased significantly by 15% over the...分析記事 • Dec 27We're Not So Sure You Should Rely on Biotoxtech's (KOSDAQ:086040) Statutory EarningsAs a general rule, we think profitable companies are less risky than companies that lose money. Having said that...Valuation Update With 7 Day Price Move • Dec 12Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩16,700, the stock is trading at a trailing P/E ratio of 57.4x, down from the previous P/E ratio of 68.9x. This compares to an average P/E of 62x in the Life Sciences industry in South Korea. Total returns to shareholders over the past three years are 127%.分析記事 • Nov 30Is Biotoxtech (KOSDAQ:086040) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Valuation Update With 7 Day Price Move • Nov 30Market bids up stock over the past weekAfter last week's 15% share price gain to ₩20,300, the stock is trading at a trailing P/E ratio of 69.7x, up from the previous P/E ratio of 60.4x. This compares to an average P/E of 102x in the Life Sciences industry in South Korea. Total returns to shareholders over the past three years are 150%.Is New 90 Day High Low • Nov 19New 90-day high: ₩16,050The company is up 59% from its price of ₩10,100 on 21 August 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 3.0% over the same period.Is New 90 Day High Low • Sep 25New 90-day high: ₩14,200The company is up 42% from its price of ₩9,970 on 26 June 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 12% over the same period.収支内訳Biotoxtech の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史KOSDAQ:A086040 収益、費用、利益 ( )KRW Millions日付収益収益G+A経費研究開発費31 Dec 2547,0171,16310,24864330 Sep 2544,1908799,22754630 Jun 2543,411-5,8289,56862231 Mar 2543,601-6,6129,99692731 Dec 2441,341-6,4279,62369430 Sep 2438,445-4,4109,85976030 Jun 2434,475-4,9439,31152931 Mar 2433,604-5,4198,63827331 Dec 2332,631-4,8789,04245430 Sep 2334,216-5,40810,24133230 Jun 2336,638-2,48710,43433231 Mar 2337,00619910,6827231 Dec 2237,2921,27810,833030 Sep 2236,2635,6848,417030 Jun 2235,4615,9107,567031 Mar 2233,9766,4626,425031 Dec 2132,7176,8325,464030 Sep 2131,1203,5265,116030 Jun 2128,5702,6335,135031 Mar 2127,2893,5505,724031 Dec 2026,4292,6145,413030 Sep 2026,3064,2375,135030 Jun 2025,9672,4265,358031 Mar 2025,679-1,4145,086031 Dec 1925,854-1,4825,056030 Sep 1922,105-4,9132,770-15330 Jun 1923,979-1,5483,526-15331 Mar 1926,632244,829-8831 Dec 1827,2454,1315,100030 Sep 1831,5675,2619,27023530 Jun 1829,9853,7358,54123531 Mar 1827,0594,8877,06517031 Dec 1725,5651,3926,2978330 Sep 1724,3302,1154,795030 Jun 1723,9921,9664,560031 Mar 1723,1961,5844,468031 Dec 1622,2571,0454,915030 Sep 1620,404-1,1736,225-1030 Jun 1618,932-1,9426,051231 Mar 1617,932-2,8736,3491231 Dec 1516,676-3,9056,4382330 Sep 1515,384-3,7905,2803130 Jun 1515,044-4,5395,47231質の高い収益: A086040には₩8.0B } という大きな 一回限りの 利益があり、過去 12 か月の財務実績が31st December, 2025に影響を及ぼしています。利益率の向上: A086040過去に利益を上げました。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: A086040過去 5 年間で収益を上げており、収益は年間-50.8%増加しています。成長の加速: A086040は昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。収益対業界: A086040昨年収益を上げたため、昨年の収益成長をLife Sciences業界 ( -29.5% ) と比較することは困難です。株主資本利益率高いROE: A086040の 自己資本利益率 ( -4.9% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/27 22:03終値2026/05/27 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Biotoxtech Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Young Ok KimDAOL Investment & Securities Co., Ltd.Seung-Ho LeeiM Securities
分析記事 • Dec 27We're Not So Sure You Should Rely on Biotoxtech's (KOSDAQ:086040) Statutory EarningsAs a general rule, we think profitable companies are less risky than companies that lose money. Having said that...
お知らせ • Mar 17Biotoxtech Co., Ltd., Annual General Meeting, Mar 27, 2026Biotoxtech Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: sky garden hall, 5806, jungbu-ro, cheongwon-gu, chungcheongbuk-do, cheongju South Korea
New Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (7.6% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩44.8b market cap, or US$30.6m).
Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩3,190, the stock trades at a trailing P/E ratio of 57x. Average trailing P/E is 17x in the Life Sciences industry in South Korea. Total loss to shareholders of 62% over the past three years.
New Risk • Nov 16New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 7.6% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (7.6% operating cash flow to total debt). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩42.6b market cap, or US$29.3m).
分析記事 • Sep 01Improved Revenues Required Before Biotoxtech Co., Ltd. (KOSDAQ:086040) Shares Find Their FeetYou may think that with a price-to-sales (or "P/S") ratio of 1.1x Biotoxtech Co., Ltd. ( KOSDAQ:086040 ) is definitely...
お知らせ • Aug 27Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces an Equity Buyback for KRW 1,000 million worth of its shares.Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million worth of its shares under the contract with Eugene Investment & Securities. The purpose of the program is to stabilize the stock price, to enhance the shareholders’ value. The program will be valid till February 26, 2026. As of August 26, 2025, the company had 237,458 shares in treasury under the dividend capacity and 0 shares in treasury under other capacities.
お知らせ • Mar 15Biotoxtech Co., Ltd., Annual General Meeting, Mar 28, 2025Biotoxtech Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 806, jungbu-ro, cheongwon-gu, chungcheongbuk-do, cheongju South Korea
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩53.7b market cap, or US$37.4m).
分析記事 • Oct 21Improved Revenues Required Before Biotoxtech Co., Ltd. (KOSDAQ:086040) Shares Find Their FeetBiotoxtech Co., Ltd.'s ( KOSDAQ:086040 ) price-to-sales (or "P/S") ratio of 2.2x might make it look like a buy right...
お知らせ • Jul 30Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces an Equity Buyback for KRW 1,000 million worth of its shares.Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million worth of its shares under the contract with Eugene Investment & Securities. The purpose of the program is to stabilize the stock price, to enhance the shareholders’ value. The program will be valid till January 29, 2025. As of July 29, 2024, the company had 30,735 shares in treasury under the dividend capacity and 0 shares in treasury under other capacities.
New Risk • Nov 28New major risk - Revenue and earnings growthEarnings have declined by 0.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 0.2% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (8.8% increase in shares outstanding). Market cap is less than US$100m (₩95.1b market cap, or US$73.4m).
New Risk • Jun 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (65% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (0.5% net profit margin). Shareholders have been diluted in the past year (8.8% increase in shares outstanding). Market cap is less than US$100m (₩123.1b market cap, or US$95.0m).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Jun 22Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩7,110, the stock trades at a trailing P/E ratio of 15.6x. Average trailing P/E is 27x in the Life Sciences industry in South Korea. Total returns to shareholders of 3.6% over the past three years.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Feb 18Investor sentiment improved over the past weekAfter last week's 31% share price gain to ₩8,990, the stock trades at a trailing P/E ratio of 32.5x. Average trailing P/E is 25x in the Life Sciences industry in South Korea. Negligible returns to shareholders over past three years.
お知らせ • Aug 25Biotoxtech Co., Ltd. announced that it has received KRW 18 billion in funding from BNK Securities Co., Ltd., Investment Arm, Mirae Asset Securities Co., Ltd. and other investorsOn August 24, 2021, Biotoxtech Co., Ltd. closed the transaction.
お知らせ • Aug 21Biotoxtech Co., Ltd. announced that it expects to receive KRW 18000 billion in funding from BNK Securities Co., Ltd., Investment ArmBiotoxtech Co., Ltd.
分析記事 • May 06Is Biotoxtech (KOSDAQ:086040) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Mar 28Estimating The Fair Value Of Biotoxtech Co., Ltd. (KOSDAQ:086040)Today we will run through one way of estimating the intrinsic value of Biotoxtech Co., Ltd. ( KOSDAQ:086040 ) by...
分析記事 • Feb 20Did Biotoxtech's (KOSDAQ:086040) Share Price Deserve to Gain 91%?Some Biotoxtech Co., Ltd. ( KOSDAQ:086040 ) shareholders are probably rather concerned to see the share price fall 32...
Is New 90 Day High Low • Feb 18New 90-day low: ₩11,200The company is down 29% from its price of ₩15,700 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 2.0% over the same period.
分析記事 • Jan 24Are Robust Financials Driving The Recent Rally In Biotoxtech Co., Ltd.'s (KOSDAQ:086040) Stock?Most readers would already be aware that Biotoxtech's (KOSDAQ:086040) stock increased significantly by 15% over the...
分析記事 • Dec 27We're Not So Sure You Should Rely on Biotoxtech's (KOSDAQ:086040) Statutory EarningsAs a general rule, we think profitable companies are less risky than companies that lose money. Having said that...
Valuation Update With 7 Day Price Move • Dec 12Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩16,700, the stock is trading at a trailing P/E ratio of 57.4x, down from the previous P/E ratio of 68.9x. This compares to an average P/E of 62x in the Life Sciences industry in South Korea. Total returns to shareholders over the past three years are 127%.
分析記事 • Nov 30Is Biotoxtech (KOSDAQ:086040) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Valuation Update With 7 Day Price Move • Nov 30Market bids up stock over the past weekAfter last week's 15% share price gain to ₩20,300, the stock is trading at a trailing P/E ratio of 69.7x, up from the previous P/E ratio of 60.4x. This compares to an average P/E of 102x in the Life Sciences industry in South Korea. Total returns to shareholders over the past three years are 150%.
Is New 90 Day High Low • Nov 19New 90-day high: ₩16,050The company is up 59% from its price of ₩10,100 on 21 August 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Sep 25New 90-day high: ₩14,200The company is up 42% from its price of ₩9,970 on 26 June 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 12% over the same period.